PCI Biotech Holding ASA (PCIB.OL)
NOK 1.33
(-0.38%)
NOK 1.33
(-0.38%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.99 Million NOK | 513.74% |
| 2022 | -633 Thousand NOK | 75.09% |
| 2021 | -2.54 Million NOK | -15.08% |
| 2020 | -2.2 Million NOK | -131.2% |
| 2019 | -955 Thousand NOK | -19000.0% |
| 2018 | -5000.00 NOK | 16.67% |
| 2017 | -6000.00 NOK | 99.96% |
| 2016 | -15.89 Million NOK | -3.8% |
| 2015 | -15.31 Million NOK | 0.0% |
| 2014 | - NOK | 0.0% |
| 2013 | - NOK | 0.0% |
| 2012 | - NOK | -100.0% |
| 2011 | 7.42 Million NOK | -28.93% |
| 2010 | 10.44 Million NOK | 21.27% |
| 2009 | 8.61 Million NOK | 16.9% |
| 2008 | 7.36 Million NOK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.71 Million NOK | 55.8% |
| 2024 Q2 | 1.71 Million NOK | 0.0% |
| 2023 Q2 | -93 Thousand NOK | -2.2% |
| 2023 FY | -371 Thousand NOK | 41.39% |
| 2023 Q4 | 1.09 Million NOK | -14.54% |
| 2023 Q3 | 1.28 Million NOK | 1483.33% |
| 2023 Q1 | -91 Thousand NOK | 42.41% |
| 2022 Q4 | -158 Thousand NOK | 0.0% |
| 2022 FY | -633 Thousand NOK | 75.09% |
| 2022 Q1 | -159 Thousand NOK | 75.5% |
| 2022 Q2 | -158 Thousand NOK | 0.63% |
| 2022 Q3 | -158 Thousand NOK | 0.0% |
| 2021 Q4 | -649 Thousand NOK | -2.2% |
| 2021 Q2 | -630 Thousand NOK | -0.48% |
| 2021 Q1 | -627 Thousand NOK | -1.79% |
| 2021 FY | -2.54 Million NOK | -15.08% |
| 2021 Q3 | -635 Thousand NOK | -0.79% |
| 2020 Q2 | - NOK | 0.0% |
| 2020 Q3 | - NOK | 0.0% |
| 2020 Q4 | -616 Thousand NOK | 0.0% |
| 2020 FY | -2.2 Million NOK | -131.2% |
| 2020 Q1 | - NOK | 0.0% |
| 2019 FY | -955 Thousand NOK | -19000.0% |
| 2019 Q2 | - NOK | 0.0% |
| 2019 Q4 | - NOK | 0.0% |
| 2019 Q3 | - NOK | 0.0% |
| 2019 Q1 | - NOK | 0.0% |
| 2018 FY | -5000.00 NOK | 16.67% |
| 2018 Q4 | - NOK | 0.0% |
| 2018 Q3 | - NOK | 0.0% |
| 2018 Q2 | - NOK | 0.0% |
| 2018 Q1 | - NOK | 0.0% |
| 2017 Q4 | - NOK | 0.0% |
| 2017 FY | -6000.00 NOK | 99.96% |
| 2017 Q1 | - NOK | 0.0% |
| 2017 Q2 | - NOK | 0.0% |
| 2017 Q3 | - NOK | 0.0% |
| 2016 Q1 | - NOK | 0.0% |
| 2016 FY | -15.89 Million NOK | -3.8% |
| 2016 Q4 | - NOK | 0.0% |
| 2016 Q3 | - NOK | 0.0% |
| 2016 Q2 | - NOK | 0.0% |
| 2015 Q3 | - NOK | 0.0% |
| 2015 FY | -15.31 Million NOK | 0.0% |
| 2015 Q1 | - NOK | 0.0% |
| 2015 Q2 | - NOK | 0.0% |
| 2015 Q4 | - NOK | 0.0% |
| 2014 Q1 | - NOK | 0.0% |
| 2014 Q2 | - NOK | 0.0% |
| 2014 Q3 | - NOK | 0.0% |
| 2014 Q4 | - NOK | 0.0% |
| 2014 FY | - NOK | 0.0% |
| 2013 Q1 | - NOK | 0.0% |
| 2013 Q2 | - NOK | 0.0% |
| 2013 Q3 | - NOK | 0.0% |
| 2013 Q4 | - NOK | 0.0% |
| 2013 FY | - NOK | 0.0% |
| 2012 Q1 | - NOK | -100.0% |
| 2012 Q4 | - NOK | 0.0% |
| 2012 Q3 | - NOK | 0.0% |
| 2012 Q2 | - NOK | 0.0% |
| 2012 FY | - NOK | -100.0% |
| 2011 Q1 | - NOK | -100.0% |
| 2011 FY | 7.42 Million NOK | -28.93% |
| 2011 Q2 | - NOK | 0.0% |
| 2011 Q3 | - NOK | 0.0% |
| 2011 Q4 | 7.42 Million NOK | 0.0% |
| 2010 Q3 | 5.55 Million NOK | 0.0% |
| 2010 Q1 | - NOK | -100.0% |
| 2010 FY | 10.44 Million NOK | 21.27% |
| 2010 Q2 | - NOK | 0.0% |
| 2010 Q4 | 1.74 Million NOK | -68.64% |
| 2009 Q4 | 2.39 Million NOK | -13.79% |
| 2009 Q3 | 2.77 Million NOK | 0.0% |
| 2009 Q2 | - NOK | 0.0% |
| 2009 FY | 8.61 Million NOK | 16.9% |
| 2008 FY | 7.36 Million NOK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arctic Bioscience AS | 9.77 Million NOK | 69.407% |
| Aqua Bio Technology ASA | 607.92 Thousand NOK | -391.835% |
| ArcticZymes Technologies ASA | 113.01 Million NOK | 97.354% |
| BerGenBio ASA | 354 Thousand NOK | -744.633% |
| Hofseth BioCare ASA | 29.87 Million NOK | 89.992% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | -2.76 Million NOK | 208.02% |